# Mendel

**Source:** https://geo.sig.ai/brands/mendel  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Challenger  
**Website:** mendel.ai  
**Last Updated:** 2026-04-14

## Summary

Clinical trial AI platform extracting structured insights from unstructured medical records; NLP for patient eligibility matching, pharmacovigilance, and real-world evidence generation.

## Company Overview

Mendel is a clinical trial data management and AI platform that accelerates pharmaceutical and biotech drug development by extracting structured insights from unstructured medical records — physician notes, pathology reports, lab results, and clinical documentation — using natural language processing to identify patients eligible for trials, adverse events, and endpoint assessments. Founded in 2017 and headquartered in San Francisco, Mendel raised approximately $35 million and serves life sciences companies, hospital systems, and CROs (contract research organizations) running clinical trials.

Mendel's platform applies clinical NLP to free-text medical records to extract structured data that standard coding and form-based data capture misses — a physician's note about a patient's symptom progression, a mention of prior therapy failure in a consultation note, or a pathology finding that determines trial eligibility. This extracted data enables more accurate patient matching for clinical trial recruitment, pharmacovigilance (detecting safety signals in real-world patient records), and evidence generation from real-world data.

In 2025, Mendel operates in the clinical AI and real-world evidence (RWE) market alongside companies like Komodo Health, Veeva Systems, Medidata (Dassault Systèmes), and Tempus for different aspects of clinical data management. The life sciences industry faces significant pressure to accelerate drug development timelines, and AI-powered clinical data extraction is viewed as a key lever for improving trial efficiency and reducing costly recruitment failures. Mendel's 2025 strategy focuses on expanding its FDA submission-ready data extraction capabilities, deepening oncology clinical trial applications where complex biomarker data requires sophisticated NLP, and growing its real-world evidence generation platform.

## Frequently Asked Questions

### What is Mendel?
Mendel AI is a clinical AI platform founded in 2017 that deciphers health data for life sciences and healthcare organizations. The company specializes in real-world data research and clinical insights to support clinical research, drug development, and healthcare analytics.

### What products and services does Mendel offer?
Mendel offers a clinical AI platform, real-world data research, health data analytics, drug development AI solutions, and clinical insights. These AI-powered solutions are designed to support clinical research and healthcare organizations.

### Who are Mendel's target customers?
Mendel serves life sciences and healthcare organizations that need clinical AI solutions. Their platform is designed for organizations involved in clinical research, drug development, and healthcare analytics.

### When was Mendel founded?
Mendel was founded in 2017. The company participated in Y Combinator's Winter 2021 (W21) cohort.

### Where is Mendel located?
Mendel is based in San Jose, California, United States.

### How much funding has Mendel raised?
Mendel has raised $60.2 million in total funding from 11 investors. The company's most recent round was a $40 million Series B in March 2022, led by Oak HC/FT.

### What are Mendel's key achievements?
Mendel raised $60.2 million in total funding including a $40 million Series B round. The company was accepted into Y Combinator's Winter 2021 cohort and joined NVIDIA's Inception Program in July 2024.

### What technology does Mendel use?
Mendel uses artificial intelligence to decipher health data and provide clinical insights. Their clinical AI platform focuses on real-world data research for healthcare and life sciences applications.

### How can I learn more about Mendel or get in contact?
Mendel is based in San Jose, California. Additional contact information was not provided in the available company details.

### What are Mendel's recent developments?
Mendel joined NVIDIA's Inception Program in July 2024. The company previously raised a $40 million Series B funding round in March 2022, led by Oak HC/FT.

## Tags

healthtech, north-america, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*